All Stories

VC-backed public offerings at lowest ebb since 2011

Ben Adams Six venture-backed IPOs raised just $ 574.5 million in the first quarter of 2016, according to the Exit Poll Report, marking the slowest quarter for these types of offerings ...

Bayer invests in U.S. growth to get it through its big transitions

Carly Helfand Plenty of Bayer's peers are focusing their expansion efforts outside the U.S., on emerging markets with more growth potential. But not the German pharma. Instead, ...

FDA leaves biosim trial data off product labels in new guidance

Carly Helfand The FDA is out with new guidance for labeling biosimilar drugs–and it may not make some drugmakers happy. Regulators dismissed pharma's request that ...

GSK wins European regulator nod for new gene therapy

Ben Adams GlaxoSmithKline has won a key recommendation from the European regulator the EMA today for Strimvelis–a groundbreaking new gene therapy for children living with an incredibly ...

Regulus shares spike on a high success rate for RG-101 hep C combos

John Carroll Can Regulus still make a splash in the increasingly crowded hepatitis C drug market? The biotech says yes, backing up its case for RG-101 with interim Phase II data that ...

Does pharma need to get cracking on Instagram? New features could be the trigger

Tracy Staton Instagram's latest updates could help pharma companies get more out of using the social app. Longer videos, for instance, give more room for drugmakers to comply with ...

Pfizer pulls thousands of bottles of children’s and infants’ Advil in Canada

Eric Palmer Parents needing to treat their children during this cold season are facing another hurdle after Pfizer pulled 126 lots of children's and infants' Advil products ...

Survey: Biopharma gets a bad grade on gender diversity

John Carroll The biopharma industry doesn't do a very good job when it comes down to the way it handles gender diversity. And if you're a woman in this business, chances are ...

UPDATED: A patient in Akashi’s suspended Duchenne MD trial dies

John Carroll A little more than a week after Cambridge, MA-based Akashi Therapeutics suspended its study of a new drug for Duchenne muscular dystrophy after a patient was sent to the ...

EMA: Faulty device didn’t distort study findings for Bayer’s Xarelto

Carly Helfand Last December, European regulators said they were no longer sure whether results from a trial of Bayer's new-age clot-buster Xarelto were accurate ...

Follow-on bonanza drives U.K. investment in life science stocks past £1B

Nick Paul Taylor At first glance, 2015 looks like the year the London Stock Exchange turned its back on biotech once again. Acacia Pharma and Shield Therapeutics both tried and failed ...

Can fast-growing Eliquis overtake J&J’s Xarelto? Bristol’s execs think so

Carly Helfand Eliquis, a new-age anticoagulant that once dragged well behind analysts' expectations, has rocketed to the top of Bristol-Myers Squibb's sales charts. And company ...
Page 2 of 83912345...102030...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS